Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: Dose adjustment recommendations

Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2014, Pages 584-592

  Vlavonou, Raphaël ^a   Perreault, Marc M ^b,c   Barrière, Olivier ^a   Shink, Eric ^d   Tremblay, Pierre Olivier ^d   Larouche, Richard ^a   Pichette, Vincent ^b,e   Tanguay, Mario ^a  

^a SYNEOS HEALTH   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d InVentiv Health Clinical   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

baclofen; dose adjustment recommendations; kidney disease; pharmacokinetics; renal impairment; safety

Indexed keywords

BACLOFEN; CREATININE; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; CENTRAL MUSCLE RELAXANT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; SINGLE DRUG DOSE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACLOFEN; CREATININE; FEMALE; GABA-B RECEPTOR AGONISTS; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84898636941     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.247     Document Type: Article

References (26)

1. Guelaud C, Similowski T, Bizec JL, Cabane J, Whitelaw WA, Derenne JP., Baclofen therapy for chronic hiccup. Eur Respir J. 1995; 8: 235-237.
2. Karila L, Gorelick D, Weinstein A, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol. 2008; 11 (3): 425-438. (Pubitemid 351482505)
3. Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA., Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial. BMC Psychiatry 2003, 3: 16, Nov 18. Available from: http://www.biomedcentral.com/content/pdf/1471-244X-3-16.pdf
4. Liu J, Wang L., Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2013; 2: CD008502.
5. Lioresal [package insert]. Novartis Pharmaceuticals UK Limited; February 2013. electronic Medicines Compendium (eMC). Datapharm Communications Ltd. < http://www.medicines.org.uk/emc/medicine/4113/SPC/Lioresal+Tablets+10mg/ > Accessed 21.05.13.
6. Wuis EW, Dirks MJM, Termind EFS, Vree TB, Van der Kleijn E., Plasma and urinary excretion kinetics of oral Baclofen in healthy subjects. Eur J Clin Pharmacol. 1989; 37: 181-184. (Pubitemid 19215459)
7. Shellenberger MK, Groves L, Shah J, Novack GD., A controlled pharmacokinetic evaluation of tizanidine and Baclofen at steady state. Drug Met Dispos. 1999; 27 (2): 201-204. (Pubitemid 29072072)
8. Su W, Yeppagan C, Carlisle EJF., Reduced level of consciousness from Baclofen in people with low kidney function. BMJ. 2009; 339: b4559. doi: 10.1136/bmj.b4559.
9. Aisen ML, Dietz M, McDowell F, Kutt H., Baclofen toxicity in a patient with subclinical renal insufficiency. Arch Phys Med Rehabil. 1994; 75: 109-111. (Pubitemid 24038836)
10. Lee TH, Chen SS, Su SL, Yang SS., Baclofen intoxication: report of four cases and review of the litterature. Clin Neuropharmacol. 1992; 15 (1): 56-62.
11. Choo YM, Kim GB, Choi JY, et al Severe respiratory depression by low dose Baclofen in the treatment of chronic hiccups in a patient undergoing CAPD. Nephron. 2000; 86: 546-547. (Pubitemid 32008870)
12. Bassilios N, Launay-Vacher V, Mercadal L, Deray G., Baclofen neurotoxicity in a chronic hemodialysis patient. Nephrol Dial Transplant. 2000; 15: 715-716. (Pubitemid 30242994)
13. Aronoff GR, Bennett WM, Berns JS, et al Drug Prescribing in Renal Failure. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
14. Lioresal [package insert]. Novartis Pharmaceuticals; December 2012. Canadian Pharmacists Association, 2013. Compendium of Pharmaceuticals and Specialties, online version (e-CPS). Available at: < https://www.e- therapeutics.ca/ > Accessed 21.05.13.
15. National Kidney Foundation, Frequently Asked Questions About GFR Estimates. National Kidney Foundation 2011. Accessed at: < http://www.kidney.org/professionals/kls/pdf/12-10-4004-KBB-FAQs-AboutGFR-1.pdf >
16. Levey AS, Lesley AS, Schmid CH, et al A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 150 (9): 604-612.
17. Steffl JL, Benett W, Olyaei AJ., The old and new methods of assessing kidney function. J Clin Pharmacol. 2012; 52: 63S-71S. National Kidney Foundation. Frequently Asked Questions About GFR Estimates. National Kidney Foundation 2011. Accessed at: < http://www.kidney.org/professionals/kls/pdf/ 12-10-4004-KBB-FAQs-AboutGFR-1.pdf >
18. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4. Definition and Classification of Stages of Chronic Kidney Disease. Availble at: < http://www.kidney.org/professionals/KDOQI/guidelines-ckd/p4-class-g1.htm > Accessed on 12.09.13.
19. FDA/CEDER resources page. Food and Drug Administration Web site. Food and Drug Administration Web site. Guidance for Industry. Bioanalytical Method Validation, May 2001. < http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf > Accessed 21.05.13.
20. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
21. FDA/CEDER resources page. Food and Drug Administration Web site. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. Draft Guidance. Revision 1. March 2010. < http://www.fda.gov/downloads/Drugs/.../Guidances/ UCM204959.pdf > Accessed 21.05.13.
22. Hulme A, MacLennan WJ, Ritchie RT, John VA, Shotton PA., Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur J Clin Pharmacol. 1985; 29: 467-469. (Pubitemid 16192605)
23. Verbeeck RK, Musuamba FT., 2009. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 65: 757-773.
24. Benett WM, Singer I, Coggins CH., A practical guide to drug usage in adult patients with impaired renal function. JAMA. 1970 214 (8): 1468-1475.
25. Dettli L., Drug dosage in renal disease. Clin Pharmacokinet. 1976; 1 (2): 126-134.
26. Chennavasin P, Brater DC., Nomograms for drug use in renal disease. Clin Pharmacokinet. 1981. 6: 193-214. (Pubitemid 12205059)